US 7944

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders
Invention	
	w named inventor(s), I/we declare that:
This declar	ation is directed to:
	The attached application, or
	Application No. PCT/EP2003/050247 filed on JUNE 20, 2003 fr.
	as amended on(if applicable);
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	
Ļ	E OF INVENTOR(S)
1	e: <u>DANIEL COHEN</u> Citizen of: <u>FRANCE</u>
Inventor tw	o: ILYA CHUMAKOV 1946
Ť	Citizen of: FRANCE
Inventor three: MARTA BLUMENFELD	
Signature:	Citizen of: _FRANCE
Inventor fo	ur: SANOBER SHAIKH
Signature:	Citizen of: GREAT BRITAIN
✓ Addi	tional inventors or a legal representative are being named ononeadditional form(s) attached hereto.

Additional inventors or a legal representative are being filamed on additional form (s) attached fiereto. This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/519336

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any a specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
EUU NAM	E OF INVENTOR(S)	
	E: MARTA PALICIO-BARRON	
	Citizen of: FRANCE	
Inventor six	: HADI ABDERRAHIM	
Signature:	Citizen of: _FRANCE	
	ven: PASCALE GREL	
Signature:	Citizen of: _FRANCE	
Inventor eig	ht:	
Signature: _	Citizen of:	
Addit	ional inventors or a legal representative are being named onadditional form(s) attached hereto.	

12 Ja4A

Rec'd PCT/PTO 25 JUL 2005

1 0 / 5 1 9 3 5 PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;		
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
FULL NAM	E OF INVENTOR(S)		
Inventor on	e: DANIEL COHEN		
Signature:	Citizen of: FRANCE		
Inventor tw	D: _ILYA CHUMAKOV		
Signature:	Citizen of: _FRANCE		
Inventor the	ee: <u>MARTA BLUMENEELD</u>		
Signature:	Citizen of: FRANCE —		
Inventor for	ır: SANOBER SHAIKH		
Signature:	Citizen of: _GREAT BRITAIN		
✓ Addit	ional inventors or a legal representative are being named on oneadditional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the below	w named inventor(s), I/we declare that:	
This declara	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
	E OF INVENTOR(S)	
	: MARTA PALICIO-BARRON  Citizen of: FRANCE	
Signature	Citizen oi. FRANCE	
	HADI ABDERRAHIM	
Signature: _	Citizen of: _FRANCE	
Inventor se	ven: PASCALE GREL	
Signature:	Citizen of: FRANCE	
Inventor eig	ht:	
Signature:	Citizen of:	
Addit	onal inventors or a legal representative are being named onadditional form(s) attached hereto.	

Rec'd PCT/PTO\_25 JUL 2005) 5 49 WAY

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
I/we have r amendmen	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;	
material to became av	Medge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which allable between the filing date of the prior application and the national or PCT International filing date of the n-in-part application.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FIII NAM	E OF INVENTOR(S)	
	e: DANIEL COHEN	
	Citizen of: FRANCE	
Inventor tw	D:_ILYA CHUMAKOV	
Signature:	Citizen of: _FRANCE	
Inventor the	ee: MARTA BLUMENFELD	
Signature:	Citizen of: FRANCE	
Unventor for	JIT: SANOBER SHAIKH	
Signature:	Sitizen of: GREAT BRITAIN	
Addit	ional inventors or a legal representative are being named on one additional form(s) attached hereto.	

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	Use of PP2A Phosphatase Modulators in the Treatment of I	Mental Disorders	
mvendon.			
As the below	w named inventor(s), I/we declare that:		
This declara	ation is directed to:		
	The attached application, or		
	Application No. PCT/EP2003/050247 , filed on JUNE 20	), 2003	
	as amended on	(if applicable);	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is	s claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the specifically referred to above;	ing the claims, as amended by any	
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
FULL NAMI	E OF INVENTOR(S)		
Inventor five	e: MARTA PALICIO-BARRON		
Signature:	Citizen of:	FRANCE	
Inventor six	::_HADI ABDERRAHIM		
Signature: _	Citizen of:	FRANCE	
Inventor se	ven: PASCALE GREL		
Signature: _	Citizen of:	FRANCE	
Inventor eight:			
Signature: _	Citizen of: _		
Additi	ional inventors or a legal representative are being named on	additional form(s) attached bereto	

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247, filed on _JUNE 20, 2003,	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any a specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
to be true, a	Into made herein of my/own knowledge are true, all statements made herein on information and belief are believed and further that these statements were made with the knowledge that willful false statements and the like are by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any ing thereon.	
	E OF INVENTOR(S)	
	e: DANIEL COHEN  Citizen of: FRANCE	
<u> </u>		
	Citizen of ERANCE	
	Citizen of: FRANCE	
	ee: MARTA BLUMENFELD	
Signature: _	Citizen of: FRANCE	
	IT: SANOBER SHAIKH	
Signature: _	Citizen of: GREAT BRITAIN	
✓ Addit	ional inventors or a legal representative are being named on oneadditional form(s) attached hereto.	

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

1. Sec. 25. 24

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
	Application No. <u>FC1/EF2003/050247</u> , filed on <u>30NE 20, 2003</u>		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;		
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
to be true, a punishable	All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAM	E OF INVENTOR(S)		
nventor five	e: MARTA PALICIO-BARRON.		
Signature:	Hartafalian Citizen of: FRANCE		
Inventor six	: HADI ABDERRAHIM		
Signature:	Citizen of: FRANCE		
Inventor se	ven: PASCALE GREL		
Signature:	Citizen of: FRANCE		
Inventor eight:			
Signature:	Citizen of:		
Addit	ional inventors or a legal representative are being named onadditional form(s) attached hereto.		
This collection (and by the U: minute to com case, Any com Officer, U.S. P	of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file SPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 plete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual ments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information atent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED HIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 .	
	as amended on(if applicable);	
I/we believe sought;	that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;	
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
CALL NAME	F OF INVENTORIES	
	E OF INVENTOR(S) e: DANIEL COHEN	
	Citizen of: FRANCE	
Inventor two	D: ILYA CHUMAKOV	
Signature: _	Citizen of: _FRANCE	
Inventor thr	ee: MARTA BLUMENFELD	
Signature: _	Citizen of: FRANCE	
Inventor for	ır: SANOBER SHAIKH	
Signature: _	Citizen of: GREAT BRITAIN	
✓ Addit	ional inventors or a legal representative are being named on oneadditional form(s) attached hereto.	

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders		
As the belo	w named inventor(s), I/we declare that:		
This declar	ation is directed to:		
	The attached application, or		
	Application No. <u>PCT/EP2003/050247</u> , filed on <u>JUNE 20, 2003</u> ,		
	as amended on(if applicable);		
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is		
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;		
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.			
EUL NAM	E OF INVENTOR(S)		
	e: MARTA PALICIO-BARRON		
ļ	Citizen of: _FRANCE		
Inventor six	::_HADLABDERRAHIM		
Signature:	Citizen of: FRANCE		
	ven: PASCALE GREL		
Signature:	Citizen of: FRANCE		
Inventor eig	pht:		
Signature:	Citizen of:		
Addit	ional inventors or a legal representative are being named onadditional form(s) attached hereto.		

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/01A (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declara	ation is directed to:	
	The attached application, or	
	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;	
material to became av	I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAMI	E OF INVENTOR(S)	
Inventor on	e: DANIEL COHEN	
Signature: _	Citizen of: FRANCE	
Inventor two	D:_ILYA CHUMAKOV	
Signature:	Citizen of: FRANCE	
Inventor thr	ee: MARTA BLUMENFELD	
Signature:	Citizen of: FRANCE	
Inventor for	ir: SANOBER SHAIKH	
Signature: _	Citizen of: GREAT BRITAIN	
✓ Addit	ional inventors or a logal representative are being named on ODB additional form/s) attached hereto	

19/519336 (09-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

#### **DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention	Use of PP2A Phosphatase Modulators in the Treatment of Mental Disorders	
As the belo	w named inventor(s), I/we declare that:	
This declar	ation is directed to:	
	The attached application, or	
:	Application No. PCT/EP2003/050247 , filed on JUNE 20, 2003 ,	
	as amended on(if applicable);	
I/we believe sought;	e that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is	
	eviewed and understand the contents of the above-identified application, including the claims, as amended by any t specifically referred to above;	
material to became av	wledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which railable between the filing date of the prior application and the national or PCT International filing date of the n-in-part application.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAM	E OF INVENTOR(S)	
Inventor fiv	e: MARTA PALICIO-BARRON	
Signature:	Citizen of: FRANCE	
Inventor six	::_HADI ABDERRAHIM	
Signature:	Citizen of: FRANCE	
Dinventor se	ven: PASCALE GREL	
Signature:	Citizen of: FRANCE	
Inventor eig	ght:	
Signature:	Citizen of:	
Addi	ional inventors or a legal representative are being named onadditional form(s) attached hereto.	

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## 10/519336

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

	Application Number	1 10/519,336	
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Filing Date	December 22, 2004	_
	First Named Inventor	Daniel Cohen	
	Title	Use of PP2A Phosphatase	_
	Art Unit		_
	Examiner Name		
		<del></del>	_

<u> </u>	Tattorney Do	CKELINGIIID	G-19403	047 01			
I hereby appoint:							
Practitioners associated with the Customer Number:  OR		23557	>				
Practitioner(s) named below:							
Name	Name Registration Number						
					<del> </del>		
as my/our attorney(s) or agent(s) to prosecute the application in Trademark Office connected therewith.	dentified above	, and to tran	sact all business	in the Ur	nited States Patent and	d	
Please recognize or change the correspondence address for the The address associated with the above-mentioned Cu			ion to:				
OR [			<del></del>			1	
The address associated with Customer Number:							
OR Firm or Individual Name							
Address							
Address		<del></del>					
City	<del></del>	State		Zip			
Country							
Telephone		Fax					
l am the:  Applicant/Inventor.  Assignee of record of the entire interest. See 37 CFR	3.71.			•			
Statement under 37 CFR 3.73(b) is enclosed. (Form F			<del> </del>		<del> </del>		
SIGNATURE of A	Applicant or A	ssignee of	Record				
Name Daniel Cohen		<del></del>					
Signature			1 Talanhana				
Date telorunia 18,7005			Telephone				
NOTE: Signatures of all the invented or assigned of record of the entire forms if more than one signature is required, see below*.	e interest or their	representativ	e(s) are required. S	ubmit mult	tiple 		
*Total of forms are submitted.							

10/5193 BCS //81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

#### POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

ed to respond to a conection of fillo	initiation unless it displays a valid Olvid Control Humber.
Application Number	10/519.336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

			· · · · · · · · · · · · · · · · · · ·		<del> </del>		
I hereby ap	point:						
✓ Prac	titioners associated v	with the Customer Number:		23557	<u> </u>		
		•					
Prac	titioner(s) named bel	low:					_
		Name			Registration N	lumber	İ
<u> </u>					-·········		
						· · · · · · · · · · · · · · · · · · ·	
-							
as my/our a Trademark	attorney(s) or agent(s Office connected the	s) to prosecute the application ic erewith.	dentified above,	and to trans	sact all business in	n the United States Patent and	d
Please reco	ognize or change the	correspondence address for th	e above-identifi	ed application	on to:		
ا ليكا	ne address associate	ed with the above-mentioned Cu	istomer Numbel	•			
OR							
Т	he address associate	ed with Customer Number:					
OR							
	Firm or Individual Name				•		
Addr	ess						
Addr	ess						
City				State	·	Zip	
Cour				Fax			
I am the:	phone			rax			
	oplicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)							
SIGNATURE of Applicant or Assignee of Record							
Name Ilya Chumakov							
Signature	Signature // U						
Date	18th reb	2005			Telephone		
	NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of forms are submitted.							

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

#### POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

	ormation unless it displays a valid UMB control number.
Application Number	10/519.336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

	<del></del>		10-134030	041 01	
I hereby appoint:					
Practitioners associated with OR	the Customer Number:	23557	>		
Practitioner(s) named below:	:				
	Name		Registration I	Number	
as my/our attorney(s) or agent(s) to Trademark Office connected therew	prosecute the application identity	ntified above, and to transac	t all business i	in the United States P	atent and
Please recognize or change the cor	rrespondence address for the a	• •	to:		*
OR	Г				
The address associated w	vith Customer Number:				
OR		· · · · · · · · · · · · · · · · · · ·			
Firm or Individual Name					
Address					
Address	***				
City		State		Zip	
Country					
Telephone		Fax			
l am the:  Applicant/Inventor.  Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)					
SIGNATURE of Applicant or Assignee of Record					
Name Hadi Abderrahim					
Signature Malirius	كذ				
Date 2 410:105			Telephone		
NOTE: Signatures of all the inventors or a forms if more than one signature is require	assignees of record of the entire in red, see below*.	nterest or their representative(s)	are required. Su	bmit multiple	
*Total of form	s are submitted.				

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

#### POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/519,336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	· ·
Attorney Docket Number	G-194US04PCT

I hereby appoint:				<u>۔۔۔۔۔</u>			•
<b>✓</b> Practitione	rs associated v	with the Customer Number:		235	557		
OR			L				
Practitione	er(s) named bel	low:					
		Name			Registration	n Number	
as my/our attorne Trademark Office	y(s) or agent(s connected the	s) to prosecute the application erewith.	ı identified	above, and to t	ransact all busines	s in the Unit	ed States Patent and
Please recognize	or change the	correspondence address for	the above	identified appli	cation to:		
	_			• •	Sation to.		
The add	Iress associate	ed with the above-mentioned (	Customer I	Number:			•
OR							
The ad	dress associate	ed with Customer Number:					
.OR		<u></u>					·
Firm	or idual Name						
Address							
Address							
City				State		Zip	
Country							
Telephone				Fax			
I am the: Applicat	nt/Inventor.			•			
Assigne Stateme	e of record of t ant under 37 Cl	the entire interest. See 37 CFI FR 3.73(b) is enclosed. (Form	R 3.71. n <i>PTO/</i> SB/§	96)			
SIGNATURE of Applicant or Assignee of Record							
Name Mart	a Blumenfeld	200					
Signature		THE DD					
Date	Jour	My 28th 2	2005		Telephone		
		s or assignees of record of the en- equired, see below*.	itire interest o	or their represent	ative(s) are required.	Submit multip	le
*Total of _		forms are submitted.					

Rec'd PCT/PTO 25 JUL 20055 794 A. 19/519336

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

#### **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS** INDICATION FORM

Under the Paperwork Reduction Act of 1995, no persons are re	guired to respond to a collection of info	ormation unless it displays a valid OMB control number.
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	10/519.336
	Filing Date	December 22, 2004
	First Named Inventor	Daniel Cohen
	Title	Use of PP2A Phosphatase
	Art Unit	
	Examiner Name	
	Attorney Docket Number	G-194US04PCT

I hereby appoint:					
Practitioners asso	ociated with the Customer Number:	23557			
Practitioner(s) na	med helow:	·.			
	med below.				
	Name	Registration Number			
as my/our attorney(s) or Trademark Office conne	agent(s) to prosecute the application identifie cted therewith.	ed above, and to transact all business in the United States Patent and			
Please recognize or cha	nge the correspondence address for the above	ve-identified application to			
	ssociated with the above-mentioned Custome				
		- Harrison			
OR					
The address a	ssociated with Customer Number:				
OR					
Firm or Individual N	ame				
Address					
Address					
City		State Zip			
Country					
Telephone		Fax			
I am the:  Applicant/Inven	tor				
Assignee of rec	ord of the entire interest. See 37 CFR 3.71.				
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)					
SIGNATURE of Applicant or Assignee of Record					
Name Sanober Sh	aikh				
Signature 5. Shull.					
Date (0/03	165	Telephone 433(0) 143 2659 86			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
*Total of forms are submitted.					

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/519336

PTO/SB/81 (09-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

#### POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/519,336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

I hereby	appoint:				
	actitioners associated v	with the Customer Number:	23557		
OR		<u> </u>			<b>-</b>
Pr	actitioner(s) named bel	low:			
I.		Name		Registration Nu	mber
					<del></del>
	<del></del>	·			
	r attorney(s) or agent(s	s) to prosecute the application identified a erewith.	above, and to trans	act all business in	the United States Patent and
Please re	ecognize or change the	correspondence address for the above-	identified application	on to	
<b>7</b>		·	• •		
<u> </u>	The address associate	ed with the above-mentioned Customer N	Number:		
OF	₹				
	The address associate	ed with Customer Number:			
OF	₹	L			
	Firm or Individual Name				
Ac	Idress		`	-	
Ac	Idress				
Ci			State		Zip
	ountry				
	lephone		Fax		
l am the	: Applicant/Inventor.				
Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)					
SIGNATURE of Applicant or Assignee of Record					
Name Marta Palicio-Barron					
Signature HartaPalico					
Date 2047ebn2ry Telephone +33376742346					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.					
_ •т	otal of f	forms are submitted.			

1 0 15 1 9 3 3 6 PTO/SB/81 (09-03)
Approach for use wrough 11-60/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/519,336
Filing Date	December 22, 2004
First Named Inventor	Daniel Cohen
Title	Use of PP2A Phosphatase
Art Unit	
Examiner Name	
Attorney Docket Number	G-194US04PCT

I hereby ap	point:					
<b>√</b> Prac	titioners associated v	with the Customer Number:	23557			
OR						
Practitioner(s) named below:						
		Name		Registration Number		
				-		
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.						
Trademark Office connected therewith.						
Please recognize or change the correspondence address for the above-identified application to:						
The address associated with the above-mentioned Customer Number:						
OR						
The address associated with Customer Number:						
OR						
	Firm or Individual Name					
Addı	ress					
Addı	ress			·		
City			State	Zip		
Cour						
	phone		Fax			
I am the:	oplicant/Inventor.					
Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)						
SIGNATURE of Applicant or Assignee of Record						
Name Pascale Grel						
Signature MOLL						
Date	18-2-	05		Telephone 01-60 - 79-66-1	4	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of forms are submitted.						